High-intensity statin therapy in patients with acute coronary
syndrome: is it enough to achieve target values?

    Authors

    Keywords

    hyperlipidemia, acute coronary syndrome, low density lipoprotein cholesterol

    DOI

    https://doi.org/10.15836/ccar2018.307

    Full Text

    Introduction : Hyperlipidemia is a major risk factor for coronary heart disease. Early treatment of hyperlipidemia following acute coronary syndrome (ACS) provides potential benefits. According to ESC Guidelines for the Management of Dyslipidaemias ( 1 ), it is recommended to initiate a high-dose statin therapy early after admission in all ACS patients, regardless of initial low-density lipoprotein cholesterol (LDL-C) values, with the aim of reaching the LDL-C goal < 1.8 mmol/L or at least a 50% reduction of LDL-C if the baseline is between 1.8 and 3.5 mmol/L. ( 1 , 2 ) The latest results of EUROASPIRE V study showed that even though the majority of patients with ACS were receiving lipid-lowering therapy, only about one in three of these patients attained the recommended LDL-C goal values. The aim of this study was to investigate how many patients discharged with the diagnosis of ACS reach the recommended LDL-C goal values at 3-month follow-up. Patients and Methods : We retrospectively analyzed 206 patients discharged with a diagnosis of ACS: 90 patients (44%) had ST-segment elevation myocardial infarction, 86 (42%) had no ST-segment elevation myocardial infarction, and 30 (14%) had unstable angina pectoris. Among patients diagnosed with ACS, 66% were men and 34% were women, with a mean age of 66.13 years old. All patients received high-dose statin therapy (atorvastatin 80 mg or rosuvastatin 40 mg), a few of them even in combination with ezetimibe. We analyzed the baseline LDL-C values during hospital admission and after discharge at 3-month follow-up. Results : The average LDL-C value during hospital admission was 3.36 mmol/L, considering that 28% of patients already had some type of lipid-lowering therapy. At 3-month follow-up the average LDL-C value was 2.19 mmol/L. The target level of LDL-C < 1.8 mmol/L was attained by 38% of patients ( Figure 1 ). Therapy effect on LDL-cholesterol reduction. LDL-C = LDL cholesterol. Conclusion : Only 38% of patients with ACS reached the LDL-C target at 3-month follow-up despite recommended therapy, which correlates with EUROASPIRE V findings. The poor goal attainment might be due to poor dietary habits and inadequate lifestyle. Therefore, we need to improve lipid management in ACS patients in secondary prevention.

    Cardiologia Croatica
    Back to search

    High-intensity statin therapy in patients with acute coronary
syndrome: is it enough to achieve target values?

    Extended Abstract
    Issue11-12
    Published
    Pages307-308
    PDF via DOIhttps://doi.org/10.15836/ccar2018.307
    hyperlipidemia
    acute coronary syndrome
    low density lipoprotein cholesterol

    Authors

    Zrinka Planinić*ORCIDUniversity Hospital „Sveti Duh“, Zagreb, Croatia
    Ante PašalićORCIDUniversity Hospital „Sveti Duh“, Zagreb, Croatia
    Tea FriščićORCIDUniversity Hospital „Sveti Duh“, Zagreb, Croatia
    Marko PerčićORCIDUniversity Hospital „Sveti Duh“, Zagreb, Croatia
    Dario GulinORCIDUniversity Hospital „Sveti Duh“, Zagreb, Croatia
    Leon AdrovićORCIDUniversity Hospital „Sveti Duh“, Zagreb, Croatia
    Jozica ŠikićORCIDUniversity Hospital „Sveti Duh“, Zagreb, Croatia

    Full Text

    Introduction : Hyperlipidemia is a major risk factor for coronary heart disease. Early treatment of hyperlipidemia following acute coronary syndrome (ACS) provides potential benefits. According to ESC Guidelines for the Management of Dyslipidaemias ( 1 ), it is recommended to initiate a high-dose statin therapy early after admission in all ACS patients, regardless of initial low-density lipoprotein cholesterol (LDL-C) values, with the aim of reaching the LDL-C goal < 1.8 mmol/L or at least a 50% reduction of LDL-C if the baseline is between 1.8 and 3.5 mmol/L. ( 1 , 2 ) The latest results of EUROASPIRE V study showed that even though the majority of patients with ACS were receiving lipid-lowering therapy, only about one in three of these patients attained the recommended LDL-C goal values. The aim of this study was to investigate how many patients discharged with the diagnosis of ACS reach the recommended LDL-C goal values at 3-month follow-up. Patients and Methods : We retrospectively analyzed 206 patients discharged with a diagnosis of ACS: 90 patients (44%) had ST-segment elevation myocardial infarction, 86 (42%) had no ST-segment elevation myocardial infarction, and 30 (14%) had unstable angina pectoris. Among patients diagnosed with ACS, 66% were men and 34% were women, with a mean age of 66.13 years old. All patients received high-dose statin therapy (atorvastatin 80 mg or rosuvastatin 40 mg), a few of them even in combination with ezetimibe. We analyzed the baseline LDL-C values during hospital admission and after discharge at 3-month follow-up. Results : The average LDL-C value during hospital admission was 3.36 mmol/L, considering that 28% of patients already had some type of lipid-lowering therapy. At 3-month follow-up the average LDL-C value was 2.19 mmol/L. The target level of LDL-C < 1.8 mmol/L was attained by 38% of patients ( Figure 1 ). Therapy effect on LDL-cholesterol reduction. LDL-C = LDL cholesterol. Conclusion : Only 38% of patients with ACS reached the LDL-C target at 3-month follow-up despite recommended therapy, which correlates with EUROASPIRE V findings. The poor goal attainment might be due to poor dietary habits and inadequate lifestyle. Therefore, we need to improve lipid management in ACS patients in secondary prevention.